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Abstract This study aimed to explore the prognosis
of very old people depending on their cardiovascular
disease (CVD) history. This observational prospective
cohort study included 570 participants aged 85 years
from the general population with 5-year follow-up for
morbidity, functional status, and mortality. At base-
line, participants were assigned to three groups: no
CVD history, “minor” CVD (angina pectoris, transient
ischemic attack, intermittent claudication, and/or heart
failure), or “major” CVD (myocardial infarction [MI],
stroke, and/or arterial surgery). Follow-up data were
collected on MI, stroke, functional status, and cause-
specific mortality. The composite endpoint included
cardiovascular events (MI or stroke) and cardiovascu-
lar mortality. At baseline, 270 (47.4 %) participants
had no CVD history, 128 (22.4 %) had minor CVD,
and 172 (30.2 %) had major CVD. Compared to the no
CVD history group, the risk of the composite endpoint
increased from 1.6 (95 % confidence interval [CI],
1.1–2.4) for the minor CVD group to 2.7 (95 % CI,
2.0–3.9) for the major CVD group. Similar trends
were observed for cardiovascular and all-cause mor-
tality risks. In a direct comparison, the major CVD
group had a nearly doubled risk of the composite
endpoint (hazard ratio, 1.8; 95 % CI, 1.2–2.7), com-
pared to the minor CVD group. Both minor and major
CVD were associated with an accelerated decline in
cognitive function and accelerated increase of disabil-
ity score (all p<0.05), albeit most pronounced in par-
ticipants with major CVD. CVD disease status in very
old age is still of important prognostic value: a history
of major CVD (mainly MI or stroke) leads to a nearly
doubled risk of poor outcome, including cardiovascu-
lar events, functional decline, and mortality, compared
with a history of minor CVD.
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Introduction
Cardiovascular disease (CVD) is characterized by a
high prevalence and incidence up to the highest age
groups. Moreover, cardiovascular morbidity is an im-
portant cause of disability and, from middle age on-
wards, CVD is the leading cause of death (Roger et al.
2011; McDermott 2007). Therefore, prevention of car-
diovascular events has high priority and risk predic-
tion models have been developed.
In daily practice, populations are usually dichot-
omized into people with known atherothrombotic
CVD, such as coronary heart disease, stroke/tran-
sient ischemic attack (TIA), and peripheral arterial
disease, and people without those manifest condi-
tions, but possibly with risk factors for CVD, such
as hypertension, hypercholesterolemia, diabetes, or
smoking (Wilson et al. 1998; Wilson 2011; Graham
et al. 2007; Dornbrook-Lavender et al. 2003). Per-
sons without manifest CVD theoretically qualify for
the so-called primary prevention, be it on a popula-
tion scale or on a more personal level when their
calculated CVD risk exceeds predefined thresholds
(Graham et al. 2007; Wald et al. 2011). Persons with
prior CVD are known to have a high risk of recur-
rent CVD (Kerr et al. 2009; Vaartjes et al. 2010;
Steg et al. 2007; van Wijk et al. 2005) and should,
therefore, receive optimal “secondary prevention,”
including lifestyle advice and preventive medication.
Despite evidence of its value also in old age, elderly
people do not receive optimal preventive treatment
even after major events (Arnold et al. 2011; Kvan et
al. 2006; Bhatt et al. 2006). At very old age, drug
interactions, intoxications, and adverse effects can
have serious impact on the quality of life (Banerjee
et al. 2011) Therefore, further risk differentiation with-
in those with prior CVD might help clinicians to select
those at the highest risk of recurrent events. In younger
age groups, it is already known that patients with prior
CVD are at the highest risk of a recurrent cardiovas-
cular event (Kerr et al. 2009). Within patients with
prior CVD, a recent study showed that a history of
ischemic events leads to a greater risk of future events
than a history of stable coronary, cerebrovascular, or
peripheral artery disease (Bhatt et al. 2010). At pres-
ent, it is unknown whether these findings can also be
applied to patients aged 85 and over.
We hypothesized that subgroups with different risks
of recurrent CVD might also be observed within the
population of the oldest old. A history of myocardial
infarction (MI) or stroke might have a different prog-
nosis than a history of relatively “minor” CVD such as
stable angina or claudication, TIA, or milder cases of
heart failure. This may have clinical consequences for
the format and intensity of secondary prevention in
these groups of older people.
We investigated whether differences in prognosis
exist between very old people with various levels of
prevalent CVD, compared to those with no manifest
CVD. Since in older populations the outcomes “mor-
bidity” and “functional status” become even more
important than mortality, we studied the prognosis
not only regarding (cause-specific) mortality, but also




The Leiden 85-plus Study is a prospective population-
based study in 85-year-old inhabitants of the city of
Leiden, The Netherlands. The study design and char-
acteristics of the cohort have previously been de-
scribed in detail (der Wiel et al. 2002; van Exel et al.
2002). In brief, between September 1997 and Septem-
ber 1999, 705 people from the 1912–1914 birth
cohorts living in the city of Leiden who reached the
age of 85 years were eligible to participate. No exclu-
sion criteria were used. From the 705 people who were
eligible at age 85, 92 refused participation and 14 died
before enrolment. A total of 599 (87 %) people gave
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informed consent and were enrolled. At baseline and
yearly up to the age of 90 years, participants were
visited at their place of residence to obtain extensive
data on health, functioning, and well-being. In addi-
tion, a medical history was obtained from the partic-
ipant’s primary care physician. For all participants,
classic cardiovascular risk factors were determined.
The Medical Ethics Committee of the Leiden Univer-
sity Medical Centre approved the study.
Prevalence of CVD at age 85 years
For each participant, the primary care physician was
interviewed about the history of CVD using a stan-
dardized questionnaire, which included questions on
present and past cardiovascular pathologies, including
MI, stroke, surgery for arterial disease (aorta, carotid,
coronary, or peripheral arteries), angina pectoris, TIA,
intermittent claudication, and heart failure. An ECG
was recorded. The presence of MI on the ECG was
defined as the presence of Minnesota Code 1-1 or 1-2
(excluding 1-2-8). Participants were assigned to three
different groups according to their CVD status: a
group with no known history of CVD (reference
group), a group with a history of “minor” CVD, and
a group with a history of “major” CVD. Minor CVD
was considered present if the primary care physician
had recorded a history of angina pectoris, TIA, inter-
mittent claudication, and/or heart failure. Major CVD
was defined as a history of MI (including MI on
baseline ECG), stroke, or surgery for arterial disease
(aorta, carotid, coronary, or peripheral arteries). These
criteria for minor and major CVD were based on
literature in younger age groups (Bhatt et al. 2006;
Rosengren et al. 1998).
Clinical endpoints
(Non)fatal myocardial infarction
Up to 90 years of age, all incident fatal and nonfatal
MIs were annually registered using data from the
primary care physician, ECGs, and death registration
forms. Incident MI on the ECG was defined as the
appearance of Minnesota Code 1-1 or 1-2 or Minne-
sota Code 1-3 in combination with the first appearance
of Minnesota Code 5-x in the same myocardial area
(Macfarlane and Latif 1996). A fatal incident MI was
categorized by cause of death codes I21–I23 (Interna-
tional Classification of Diseases [ICD]-10).
(Non)fatal stroke
Information on incident stroke was collected annually
from the primary care physician up to 90 years of age.
A fatal incident stroke was categorized by cause of
death codes I61–I69 (ICD-10).
Incident cardiovascular events or cardiovascular
mortality
The composite endpoint “incident cardiovascular
events or cardiovascular mortality” was defined as
fatal and nonfatal MI, fatal and nonfatal stroke, or
other cardiovascular mortality.
Mortality
All participants were followed up for mortality until
the age of 95 years. Dates and causes of death were
obtained from civic and national registries. Causes of
death were divided into cardiovascular causes (ICD-
10 codes I00–I99) and noncardiovascular causes (all
other ICD-10 codes). Assignment of cause of death
was done blinded for baseline and follow-up study
data.
Functional status
Up to 90 years of age, participants were annually
visited by a research nurse at their place of resi-
dence. Cognitive function was assessed by the
Mini-Mental State Examination (MMSE) with
scores ranging from 0 to 30 points (optimal)
(Tombaugh and McIntyre 1992). Disability was
assessed using the Activities of Daily Living
(ADL) items from the Groningen Activity Restric-
tion Scale with scores ranging from 9 (optimal) to
36 points (Kempen et al. 1996). In those with
MMSE scores above 18, Cantril’s Ladder of Life
with a score from 1 to 10 (optimal) points was
used as a measure of general well-being (Cantril
1965) and the 15-item Geriatric Depression Scale
(GDS) with scores ranging from 0 (optimal) to 15
points was used to screen for depressive symptoms
(de Craen et al. 2003).
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Table 1 Baseline characteristics of participants from the Leiden 85-plus Study (n0570), depending on cardiovascular history
Total CVD history p for trenda
570 (100) None 270 (47.4) Minor 128 (22.4) Major 172 (30.2)
Sociodemographic characteristics
Women 379 (67) 195 (72) 93 (73) 91 (53) <0.001
Net monthly income >750€ 276 (49) 147 (55) 52 (41) 77 (45) 0.058
Post primary school education 197 (35) 104 (39) 41 (32) 52 (31) 0.091
Noninstitutionalized living 467 (82) 229 (85) 105 (82) 133 (77) 0.048
Functional status
Cognitive function (MMSE) 26 (22–28) 27 (24–29) 26 (23–28) 25 (19–28) <0.001
ADL disability 10 (9–15) 10 (9–13) 10 (9–15) 10 (9–16) 0.009
Subjective well-being (Cantril) b 8 (7–9) 8 (6–9) 8 (7–8) 8 (7–9) 0.177
Depressive symptoms (GDS) b 2 (1–3) 2 (1–3) 2 (1–4) 2 (1–3) 0.636
Cardiovascular characteristics
Classic risk factors
Hypertension c 325 (58) 134 (50) 87 (68) 104 (64) 0.003
RR systolic, mmHg 154 (143–166) 155 (144–166) 154 (142–168) 153 (141–166) 0.332
Hypercholesterolemia d 123 (22) 59 (22) 30 (24) 34 (22) 0.928
Total cholesterol, mmol/L 5.7 (4.9–6.4) 5.7 (5.0–6.4) 5.8 (4.9–6.4) 5.6 (4.8–6.3) 0.320
HDL cholesterol, mmol/L 1.3 (1.0–1.6) 1.3 (1.1–1.6) 1.3 (1.0–1.5) 1.1 (0.9–1.4) <0.001
BMI, kg/m² 27 (24–30) 27 (25–30) 27 (24–31) 26 (24–29) 0.096
Diabetes e 89 (16) 38 (14) 19 (15) 32 (20) 0.151
Smoking f 267 (49) 122 (46) 54 (42) 91 (58) 0.029
Medication use
Blood pressure lowering drugs g 316 (57) 111 (42) 92 (72) 113 (71) <0.001
Anticoagulants/aspirin 162 (28) 28 (10) 46 (36) 88 (51) <0.001
Lipid-lowering drugs 6 (1) 1 (0.4) 2 (1.6) 3 (1.7) 0.15
Cardiovascular history
Angina 109 (19) 0 60 (48) 49 (29)
Transient ischemic attack 75 (13) 0 40 (31) 35 (21)
Intermittent claudication 37 (7) 0 12 (10) 25 (15)
Heart failure 74 (13) 0 36 (28) 38 (22)
Myocardial infarction 99 (17) 0 0 99 (58)
Stroke 61 (11) 0 0 61 (36)
Surgery for arterial disease h 42 (7) 0 0 42 (25)
Data presented as n (%) for categorical variables, and median (IQR) for continuous variables
CVD = cardiovascular disease; No CVD = participants with no history of CVD; Minor CVD = participants with a history of angina,
transient ischemic attack, intermittent claudication or heart failure; Major CVD = participants with a history of myocardial infarction,
stroke or surgery for arterial disease ; MMSE = Mini-Mental State Examination (range 0-30); ADL = basic activities of daily living
(range 9-36); Cantril = Cantril’s ladder of life (range 0–10); GDS = Geriatric Depression Scale (range 0–15)
a Chi-square test for categorical variables and Jonckheere-Terpstra for continuous variables;
b assessed only in participants with MMSE >18; c RR ≥160 systolic at baseline or a history of hypertension; d total cholesterol ≥6.5 at
baseline or statin use; e history of diabetes, antidiabetic medication use or non-fasting glucose ≥11 mmol/L; f current or past smoker; g
use of β-blockers, ACE inhibitors, diuretics or calciumchannel blockers as reported by the participants pharmacists
h aorta, carotid, coronary or peripheral arteries
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Statistical analysis
Differences in baseline characteristics between the
groups according to CVD status were analyzed with the
chi-square test for categorical variables and the Jonck-
heere–Terpstra test for continuous variables. Time-to-
event curves were constructed with the Kaplan–Meier
method and compared using a log-rank test. If no exact
time to event was available, the time to event was calcu-
lated as halfway that particular year. Mortality and mor-
bidity hazard ratios (HR) and corresponding 95 %
confidence intervals (CIs) were calculated in a Cox pro-
portional hazards model adjusted for sex. The same HRs
were calculated in a model with additional adjustments
for the use of antihypertensive medication, income, and
level of education. Incidence rate was calculated using
the timetable method as number of incidents per 1,000
person-years at risk with corresponding 95%CIs. Differ-
ences in cognitive function (MMSE), changes in disabil-
ity (ADL), general well-being (Cantril), and depressive
symptoms (GDS) were estimated using linear mixed
models adjusted for sex and are presented as (predicted)
means with standard errors. As a first sensitivity analysis,
the stratification in groups according to CVD status was
repeated at the age of 90 years, with updated information
about incidence of cardiovascular events from 85 to
90 years of age. A second sensitivity analysis was done
with risk groups according to site of CVD: a group with a
history of cardiac CVD (angina pectoris and/or MI), a
group with a history of cerebrovascular CVD (TIA and/
or stroke), a group with a history of peripheral CVD
(intermittent claudication and/or surgery for noncoronary
arterial disease), and a group with a history of CVD at
multiple sites. Data analysis was performed using SPSS
17.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
For 570 of the 599 participants, all baseline measure-
ments were available. At 85 years of age, 270 (47.4 %)
participants had no history of CVD, 128 (22.4 %) partic-
ipants hadminor CVD, and 172 (30.2%) participants had
major CVD (Table 1). Participants with major CVDwere
more often men (47 versus 27 % for minor CVD and
28 % for no CVD, ptrend<0.001) and more often institu-
tionalized (23 versus 18 % for minor CVD and 15 % for
no CVD, ptrend00.048). They had higher scores of dis-
ability (ptrend00.009) and their MMSE scores were the
lowest (ptrend<0.001). Only 36 % of the participants with
minor CVD and 51 % of the participants with major
CVD used aspirin or oral anticoagulants. Median systolic
Fig. 1 History of CVD and 5-year incidence of the composite
endpoint “MI, stroke, and cardiovascular mortality” (left panel),
as well as incidence of all-cause mortality (right panel) for three
groups with no history of CVD, a history of minor CVD, and a
history of major CVD, respectively. Thick solid linemajor CVD,
thin solid line minor CVD, dashed line no CVD
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blood pressure was 154 mmHg (interquartile range
[IQR], 143–166), median total cholesterol was
5.7 mmol/L (IQR, 4.9–6.4). Participants with major
CVD had lower HDL cholesterol levels (ptrend<0.001).
Use of statins was minimal: no more than 1 % of all
participants used lipid-lowering drugs. From all partici-
pants with heart failure (n074), more than half (n038
[51 %]) also had a history of major CVD.
At 90 years of age, 303 (53 %) participants were
still alive. Follow-up for mortality was complete, and
for 296 participants, we completed all clinical meas-
urements at 90 years.
Morbidity and mortality
During 5 years of follow-up, 181 (32 %) participants
reached the composite endpoint, including 76 (42 %)
fatal and nonfatal MI, 76 (42 %) fatal and nonfatal
strokes, and 29 (16 %) additional cardiovascular deaths.
Figure 1 shows the Kaplan–Meier curves for the three
groups for the composite endpoint “incident cardiovas-
cular events or cardiovascular mortality” (left panel) and
all-cause mortality (right panel). Overall, during these
5 years, 267 (47 %) participants died; of which, 106
(40 %) died from cardiovascular causes. The incidence
rate for “incident cardiovascular events or cardiovascular
mortality” increased from 56 (95 % CI, 44–72) per 1,000
person-years at risk in the group with no CVD to 88
(95 % CI, 65–118) in the group with minor CVD and to
164 (95 % CI, 144–199) in the group with major CVD
(Table 2). The risks for a fatal or nonfatal MI, a fatal or
nonfatal stroke, and the composite endpoint increased
from 1.7 (95 % CI, 0.9–3.1), 1.7 (95 % CI, 0.9–3.2),
and 1.6 (95 % CI, 1.1–2.4), respectively, in participants
Table 2 Five-year hazard ratios and absolute risks of cardiovascular morbidity and mortality, depending on cardiovascular history
adjusted for sex (n0570)












HR 1 1.7 (0.9–3.1) 2.6 (1.6–4.5) 0.001 1.8 (0.97–3.2)
No. of events 25 (9.3) 17 (13.3) 34 (19.8)
Incidence rate 23 (15–33) 37 (23–58) 65 (47–90)
Fatal and nonfatal
stroke
HR 1 1.7 (0.9–3.2) 3.4 (2.0–5.8) <0.001 2.0 (1.1–3.6)
No. of events 23 (8.5) 16 (12.5) 37 (21.5)
Incidence rate 20 (14–30) 35 (21–56) 69 (51–94)
CV events or CV
mortalitya
HR 1 1.6 (1.1–2.4) 2.7 (2.0–3.9) <0.001 1.8 (1.2–2.7)
No. of events 61 (22.6) 39 (30.5) 81 (47.1)
Incident rate 56 (44–72) 88 (65–118) 164 (144–199)
Mortality Cardiovascular HR 1 2.0 (1.1–3.4) 3.7 (2.3–5.8) <0.001 1.9 (1.2–3.1)
No. of events 29 (10.7) 23 (18.0) 54 (31.4)
Incidence rate 25 (18–36) 48 (32–71) 95 (74–122)
Noncardiovascular HR 1 1.5 (1.03–2.3) 1.7 (1.2–2.5) 0.001 1.1 (0.7–1.7)
No. of events 66 (24.4) 40 (31.3) 55 (32.0)
Incidence rate 57 (54–72) 83 (62–111) 97 (75–124)
All-cause HR 1 1.7 (1.2–2.3) 2.3 (1.7–3.1) <0.001 1.4 (1.02–1.9)
No. of events 95 (35.2) 63 (49.2) 109 (63.4)
Incidence rate 82 (68–100) 131 (104–164) 193 (162–227)
Data are presented as HR with corresponding 95 % CIs, absolute numbers of events (%), and incidence rates as number of incidents per
1,000 person-years at risk with corresponding 95 % CIs
CVD cardiovascular disease, No CVD participants with no history of CVD, Minor CVD participants with a history of angina, TIA,
intermittent claudication, or heart failure, Major CVD participants with a history of MI, stroke, or surgery for arterial disease (aorta,
carotid, coronary, or peripheral arteries)
a Composite endpoint: fatal and nonfatal MI, fatal and nonfatal stroke, and cardiovascular mortality
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with minor CVD to 2.6 (95 %CI, 1.6–4.5), 3.4 (95 %CI,
2.0–5.8), and 2.7 (95 % CI, 2.0–3.9), respectively, in
those with major CVD. In a direct comparison of the
group with major CVD with the group with minor CVD,
the risk of the composite endpoint was nearly doubled in
the major CVD group (HR, 1.8; 95 % CI, 1.2–2.7).
For cardiovascular mortality, the risks increased
from 2.0 (95 % CI, 1.1–3.4) in the minor CVD group
to 3.7 (95 % CI, 2.3–5.8) in the major CVD group
(ptrend<0.001). For all-cause mortality, the risks rose
from 1.7 (95 % CI, 1.2–2.3) in the minor group to 2.3
(95 % CI, 1.7–3.1) in the major group (ptrend<0.001).
After adjustment for the use of antihypertensive
medication, income, and level of education, all
these estimates remained roughly similar (data not
shown).
When we analyzed the HRs with 10-year follow-up,
we found similar risks for cardiovascular and all-cause
mortality: HR, 1.5 (95 % CI, 0.99–2.2) and 1.4 (95 %
CI, 1.1–1.8), respectively, for minor CVD and HR, 2.6
(95 % CI, 1.9–3.7) and 2.0 (95 % CI, 1.6–2.5), respec-
tively, for major CVD.
Functional status
At baseline, there were no differences in functional
status between participants with minor CVD and
those with no CVD (Table 3; Fig. 2). But the MMSE
score was lower (−2.8 points, p<0.001) and ADL
disability score was higher (2.6 points, p00.003) in
participants with major CVD. Compared to partic-
ipants with no CVD, participants with minor CVD
had an additional annual decrease in MMSE score of
−0.19 points (p00.023) and increase in ADL disability
score of 0.25 points (p00.042) over time. Participants
with major CVD had an additional annual decrease in
MMSE score (−0.24 points, p00.005) and increase
in ADL disability score (0.61 points, p<0.001).
Compared to participants with minor CVD, partic-
ipants with major CVD had an additional annual
increase in ADL disability score of 0.36 points
(p00.023). All other changes in functional status
over time were not significant.
Sensitivity analyses
At 90 years of age, participants were recategorized
with the updated clinical information from 85 to
90 years of age. Of the participants with complete data
at 90 years of age (n0296), 119 (40 %) had no history
of CVD, 93 (31 %) had minor CVD, and 84 (28 %)
had major CVD. In participants with minor CVD, the
5-year risk for cardiovascular mortality (up to 95 years
of age) was not significantly increased (1.1; 95 % CI,
0.6–1.9), but participants with major CVD had a more
than twofold increased risk (HR, 2.1; 95 % CI, 1.2–
3.7). For all-cause mortality, the HRs were 1.1 (95 %
CI, 0.79–1.5) and 2.1 (95 % CI, 1.5–3.0), respectively.
The second sensitivity analysis was done with differ-
ent groups according to the site of their CVD. There were
Table 3 Association between history of cardiovascular disease at 85 years of age and (changes in) functional status from 85 through
90 years of age (n0570)
Cross-sectional effecta Annual effect
reference group
Additional annual effecta
Minor CVD Major CVD Minor CVD Major CVD
B (SE) p value B (SE) p value B (SE) p value B (SE) p value B (SE) p value
MMSE −0.65 (0.69) 0.35 −2.8 (0.69) <0.001 −0.67 (0.045) <0.001 −0.19 (0.084) 0.023 −0.24 (0.085) 0.005
ADL disability 0.58 (0.71) 0.41 2.6 (0.72) 0.003 1.1 (0.066) <0.001 0.25 (0.12) 0.042 0.61 (0.13) <0.001
Cantril scale of
well-being
−0.021 (0.17) 0.90 0.24 (0.17) 0.15 −0.20 (0.021) <0.001 0.039 (0.041) 0.35 −0.045 (0.043) 0.29
Geriatric depression
scale
0.060 (0.31) 0.85 0.033 (0.31) 0.92 0.30 (0.035) <0.001 −0.023 (0.069) 0.74 0.030 (0.070) 0.66
Associations were assessed by linear mixed models adjusted for sex. Scale: MMSE, 0–30 points; ADL disability, 9–36 points; Cantril,
0–10 points; GDS of depressive symptoms, 0–15 points
CVD cardiovascular disease
a Reference group: group with no CVD at baseline
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25 participants (4.4%) with peripheral CVD, 73 (12.8%)
with cerebrovascular CVD, 109 (19.1 %) with cardiac
CVD, and 66 (11.6 %) with CVD on more than one site
(Table 4). HRs were all calculated with the group with no
CVD as reference group. The HR for fatal or nonfatal
stroke was as high as 3.9 (95 % CI, 2.2–6.9) for those
with previous TIA or stroke, and the HR for fatal or
nonfatal MI was particularly high (3.4; 95 % CI, 1.9–
6.4) in the group with CVD onmultiple sites. The HR for
cardiovascular mortality was highest in participants with
peripheral CVD (3.8; 95 % CI, 1.7–8.5). In contrast with
this high risk of cardiovascular mortality, the HRs for
fatal or nonfatal MI and fatal or nonfatal stroke in partic-
ipants with peripheral CVD were low, nearly equal to the
group with no CVD (1.0; 95 % CI, 0.23–4.3 and 1.4;
95 % CI, 0.32–5.8, respectively). Except for the above-
mentioned HRs, the groups did not differ materially.
Discussion
In this cohort of oldest old from the general population,
participants with a history ofmajor CVDhad amarkedly
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Fig. 2 Changes in cognitive function, disability, subjective
well-being, and depressive symptoms over time as estimated
from linear mixed models adjusted for sex. Data are presented as
the means with standard errors. Triangles reference group with
no history of CVD, squares minor CVD, diamonds major CVD
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decline, as well as cardiovascular and all-cause mortal-
ity. Patients with a history of minor CVD had a relatively
better prognosis: in nonagenarians, a history of minor
CVD was not associated with mortality anymore. This
implies that, within the group of very old patients who
are eligible for secondary prevention, different risk
groups can now be identified on the basis of clinical
information only. Since the prevention of morbidity and
subsequent loss of independency is increasingly impor-
tant in the aging Western societies, cardiovascular pre-
vention remains essential up to the highest age groups.
Our findings underscore the importance of adequate
secondary preventive measures in those with a history
of major cardiovascular events, since these measures
have been shown to be effective up to high ages
(Andrawes et al. 2005; Alhusban and Fagan 2011;
Castilla-Guerra et al. 2009; Asberg et al. 2010; Ray et
al. 2006; Deedwania et al. 2007; Shepherd et al. 2002;
Wenger and Lewis 2010; Thomas et al. 2010). On the
other hand, our results suggest that the potential yield of
secondary preventive measures in the oldest old might
be less in older persons with a history of minor CVD.
Our study is the first to analyze prognosis based on
a history of “minor” and “major” CVD in the general
population of the oldest old. This distinction between
minor and major CVD is based on the difference in
risk of cardiovascular events and mortality after angi-
na or TIA compared with the risk after an MI or
stroke, which has been described in younger patients
(Arima et al. 2006; Rosengren et al. 1998; Hjemdahl et
al. 2006). Our study now also showed a significant
difference in cardiovascular morbidity and mortality
between groups with a history of minor and major
CVD in participants aged 85 years and over.
Most other studies, performed in younger age
groups, have evaluated risks after an event in a
specific cardiovascular bed (cardiac, cerebral, or
peripheral) (Migliaccio-Walle et al. 2010; Bhatt et
al. 2009; Arima et al. 2006; Touze et al. 2005) or
observed differences in risk between one or multiple
CVD sites (Ferrieres et al. 2006; Migliaccio-Walle et
al. 2010; Bhatt et al. 2009; Steg et al. 2007). The
high risk of recurrent stroke in the group with a
history of TIA or stroke that we observed is in line
with previous studies (Steg et al. 2007; Arima et al.
2006; Ferrieres et al. 2006; Vickrey et al. 2002).
In keeping with earlier reports, in the present study,
the risk of cardiovascular mortality was remarkably
high in participants with peripheral artery disease,
whereas cardiovascular morbidity risk in this group
was relatively low (Ferrieres et al. 2006; Steg et al.
2007; Arima et al. 2006; Vickrey et al. 2002). In
contrast with younger age groups, mortality risks in
our study were not higher in participants with
multiple-site CVD (Steg et al. 2007; Bhatt et al.
2009; Migliaccio-Walle et al. 2010; Ferrieres et al.
2006). In very old age, it seems that major CVD,
rather than multiple CVD, is of prognostic value.
Previous studies have revealed a significant decline
in physical functioning after stroke and MI in 70-year-
olds (van Jaarsveld et al. 2001; Newman et al. 2009)
and a negative impact on neurocognitive function
Table 4 Five-year hazard ratios for cardiovascular morbidity and mortality for participants, depending on specific site of cardiovas-












Morbidity Fatal and nonfatal MI 1 2.0 (1.1–3.7) 1.9 (0.96–3.9) 1.0 (0.23–4.3) 3.4 (1.9–6.4)
Fatal and nonfatal stroke 1 2.3 (1.3–4.2) 3.9 (2.2–6.9) 1.4 (0.32–5.8) 1.6 (0.68–3.7)
CV events or CV mortalitya 1 2.0 (1.4–3.0) 2.3 (1.5–3.5) 1.9 (0.93–3.8) 2.5 (1.6–3.9)
Mortality Cardiovascular 1 2.8 (1.7–4.6) 3.0 (1.7–5.3) 3.8 (1.7–8.5) 3.1 (1.7–5.5)
Noncardiovascular 1 1.4 (0.90–2.1) 1.5 (0.95–2.4) 1.6 (0.76–3.3) 1.6 (1.0–2.6)
All-cause 1 1.8 (1.3–2.5) 2.0 (1.4–2.8) 2.2 (1.3–3.8) 2.0 (1.4–3.0)
Data are presented as HR with corresponding 95 % CIs
CVD cardiovascular disease, Cardiac angina or MI, Cerebrovascular TIA or stroke, Peripheral claudication or operation for non-
coronary arterial disease, Multiple sites CVD on more than one of cardiac, cerebrovascular, or peripheral sites
a Composite endpoint: fatal and nonfatal MI, fatal and nonfatal stroke, and cardiovascular mortality
AGE (2013) 35:1433–1444 1441
(Waldstein and Wendell 2010; Newman et al. 2005,
2009). Our study confirmed these data in the very old.
Our study has several strengths. First, our results can
be easily applied in day to day medical practice. The
current electronic medical records provide clinicians a
rapid overview of the cardiovascular history without any
extra costs or effort. Secondly, our population-based
study had a high participation rate (87 %) and no exclu-
sion criteria, both allowing our conclusions to be gener-
alized to the oldest old in the general population. Finally,
we studied multiple relevant outcomes for an ageing
population: mortality, morbidity, and functional status.
A limitation might be that CVD history was based on
the diagnosis of the primary care physicians, using
variable diagnostic standards. However, this reflects
clinical reality in primary care and previous research
has shown the accuracy of data recorded in general
practice to be very high (Hassey et al. 2001). In view
of the fact that this study was the first to discriminate
major and minor CVD in very old age, we recommend
that this analysis be repeated in another cohort.
Evidence that medication for secondary cardio-
vascular prevention is recommendable up to the
highest age groups is increasing (Andrawes et al.
2005; Alhusban and Fagan 2011; Castilla-Guerra et
al. 2009; Asberg et al. 2010; Maroo et al. 2008; Ray
et al. 2006; Deedwania et al. 2007; Shepherd et al.
2002; Wenger and Lewis 2010; Thomas et al. 2010).
In this cohort, the use of secondary preventive med-
ication was far from optimal, leaving room for im-
provement. From our results, it can be derived that
distinct groups are discernible within those who
should receive secondary prevention. This is an im-
portant finding, since at very old age, polypharmacy
(Banerjee et al. 2011; Fleg et al. 2011), treatment adher-
ence (Kvan et al. 2006), and the delicate balance be-
tween benefit and harm (Cardenas-Valladolid et al.
2010; Kvan et al. 2006; Fleg et al. 2011) raise a chal-
lenge for clinicians in day to day practice (Anthierens et
al. 2010; Fried et al. 2011). The results of our study may
help them to make appropriate treatment decisions, tak-
ing all relevant prognostic information into account.
In conclusion, in very old age, the CVD history is
an easy tool for clinicians to identify patients who are
at high risk for new cardiovascular events, functional
decline, and cardiovascular mortality, as well as all-
cause mortality. A history of major CVD nearly dou-
bles the risk of a recurrent cardiovascular event or
cardiovascular mortality compared with a history of
minor CVD. Our results encourage both physicians
and 85-year-olds with a history of major CVD to
maximize their cardiovascular preventive efforts.
However, when adverse effects or harmful interactions
arise in a very old patient with minor CVD, the bal-
ance between benefit and harm could change and strict
continuation of preventive medication might be
reconsidered.
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